If you haven’t received the pneumonia (pneumococcal) vaccine, you’re among the majority of Americans. Just one in four (25%) people at high risk of pneumococcal disease, an infection that ...
In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...
Doctors generally recommend vaccines against COVID-19, RSV and flu to help protect against some of the infections that can cause pneumonia. Also available is the pneumococcal vaccine which not only ...
The following is a summary of “A nationwide study of two decades of invasive pneumococcal disease in the Faroe Islands, ...
SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...
Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback